Menu Search
Equities

OptiBiotix Health PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
OB3:FRA

OptiBiotix Health PLC

Actions
  • Price (EUR)0.069
  • Today's Change-0.005 / -6.76%
  • Shares traded100.00
  • 1 Year change-60.57%
  • Beta3.0831
Data delayed at least 15 minutes, as of Feb 13 2026 19:26 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

OptiBiotix Health Plc is a life sciences company. The Company is engaged in the development of microbial strains, compounds, and formulations, which are used as active ingredients and supplements. It is focused on the development of products which reduce hunger and food cravings, enhance the gut microbiome, and provide a healthy substitute for sugar. It is also developing its own range of consumer supplements and health products. Its areas of focus include obesity, cardiovascular health, and diabetes. Its products include SlimBiome, CholBiome, SweetBiotix, WellBiome, OptiBiotics and SlimBiome X3. SlimBiome offers a natural, scientifically supported, non-pharmaceutical approach to reducing hunger and cravings. CholBiome contains Lactobacillus plantarum LPLDL as the only active ingredient, focusing on healthy cholesterol maintenance and delivering tangible health benefits. SweetBiotix is a zero or low-calorie, prebiotic, and a smarter alternative to sugar and existing sweeteners.

  • Revenue in GBP (TTM)1.15m
  • Net income in GBP-191.00k
  • Incorporated2006
  • Employees5.00
  • Location
    OptiBiotix Health PLCInnovation CentreInnovation Way, HeslingtonHESLINGTON Y010 5DGUnited KingdomGBR
  • Phone+44 207 933 8780
  • Websitehttp://www.optibiotix.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.